Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study

Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study

Background: Although the immune checkpoint inhibitors, nivolumab and pembrolizumab, were found to be promising in patients with advanced NSCLC, some of them either do not respond or have recurrence after an initial response. It is still unclear who will benefit from these therapies, and, hence, ther...

ver descrição completa

Detalhes bibliográficos
Main Authors: Sevinj Yolchuyeva, PhD, Elena Giacomazzi, MSc, Marion Tonneau, PhD, Fabien Lamaze, PhD, Michele Orain, MT, François Coulombe, MD, Julie Malo, CCRP, Wiam Belkaid, PhD, Bertrand Routy, MD, PhD, Philippe Joubert, MD, PhD, Venkata S.K. Manem, MSc, PhD
Formato: Artigo
Idioma:English
Publicado em: Elsevier 2023-12-01
Colecção:JTO Clinical and Research Reports
Assuntos:
Radiomics
Machine learning
Immunotherapy
Biomarker discovery
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2666364323001455

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001455

Registos relacionados